Synergistic induction of apoptosis by HMG-CoA reductase inhibitor and histone deacetylases inhibitor in HeLa cells

Biochemical and Biophysical Research Communications

Volumn 365, Issue 2, 2008, Pages 386-392

  Gan, Yehua ^a,b   Wang, Jian ^b   Coselli, Joseph ^b   Wang, Xing Li ^b  

^a PEKING UNIVERSITY   (China)

^b TEXAS HEART INSTITUTE   (United States)

Author keywords

Apoptosis; HMG CoA; RhoA; Statin; TSA

Indexed keywords

COMPACTIN; GERANYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STATIN; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; HELA CELL; HUMAN; HUMAN CELL; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ACYL COENZYME A; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN;

EID: 36348996422     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.11.002     Document Type: Article

References (40)

1. Winter-Vann A.M., and Casey P.J. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat. Rev. Cancer 5 (2005) 405-412
2. Fritz G. HMG-CoA reductase inhibitors (statins) as anticancer drugs (review). Int. J. Oncol. 27 (2005) 1401-1409
3. Sagami H., Morita Y., Korenaga T., and Ogura K. Purification of geranylgeranyl diphosphate synthase from bovine brain. Acta Biochim. Pol. 41 (1994) 293-302
4. Jones K.D., Couldwell W.T., Hinton D.R., Su Y., He S., Anker L., and Law R.E. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem. Biophys. Res. Commun. 205 (1994) 1681-1687
5. Ghosh P.M., Ghosh-Choudhury N., Moyer M.L., Mott G.E., Thomas C.A., Foster B.A., Greenberg N.M., and Kreisberg J.I. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 18 (1999) 4120-4130
6. Rubins J.B., Greatens T., Kratzke R.A., Tan A.T., Polunovsky V.A., and Bitterman P. Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Respir. Crit. Care Med. 157 (1998) 1616-1622
7. Li X., Liu L., Tupper J.C., Bannerman D.D., Winn R.K., Sebti S.M., Hamilton A.D., and Harlan J.M. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J. Biol. Chem. 277 (2002) 15309-15316
8. Blanco-Colio L.M., Villa A., Ortego M., Hernandez-Presa M.A., Pascual A., Plaza J.J., and Egido J. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 161 (2002) 17-26
9. Denoyelle C., Albanese P., Uzan G., Hong L., Vannier J.P., Soria J., and Soria C. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal 15 (2003) 327-338
10. Zhong W.B., Wang C.Y., Chang T.C., and Lee W.S. Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 144 (2003) 3852-3859
11. Cafforio P., Dammacco F., Gernone A., and Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26 (2005) 883-891
12. Roskoski Jr. R. Protein prenylation: a pivotal posttranslational process. Biochem. Biophys. Res. Commun. 303 (2003) 1-7
13. Aznar S., Fernandez-Valeron P., Espina C., and Lacal J.C. Rho GTPases: potential candidates for anticancer therapy. Cancer Lett. 206 (2004) 181-191
14. Schmidt K., Gust R., and Jung M. Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells. Arch. Pharm. (Weinheim) 332 (1999) 353-357
15. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., and Richon V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60 (2000) 5165-5170
16. Herold C., Ganslmayer M., Ocker M., Hermann M., Geerts A., Hahn E.G., and Schuppan D. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J. Hepatol. 36 (2002) 233-240
17. Donadelli M., Costanzo C., Faggioli L., Scupoli M.T., Moore P.S., Bassi C., Scarpa A., and Palmieri M. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol. Carcinog. 38 (2003) 59-69
18. Duan H., Heckman C.A., and Boxer L.M. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol. Cell. Biol. 25 (2005) 1608-1619
19. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13 (2001) 477-483
20. Melnick A., and Licht J.D. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr. Opin. Hematol. 9 (2002) 322-332
21. Nimmanapalli R., Fuino L., Stobaugh C., Richon V., and Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101 (2003) 3236-3239
22. Maggio S.C., Rosato R.R., Kramer L.B., Dai Y., Rahmani M., Paik D.S., Czarnik A.C., Payne S.G., Spiegel S., and Grant S. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 64 (2004) 2590-2600
23. Rahmani M., Reese E., Dai Y., Bauer C., Payne S.G., Dent P., Spiegel S., and Grant S. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res. 65 (2005) 2422-2432
24. Gao N., Rahmani M., Shi X., Dent P., and Grant S. Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress. Blood 107 (2006) 241-249
25. Rossig L., Li H., Fisslthaler B., Urbich C., Fleming I., Forstermann U., Zeiher A.M., and Dimmeler S. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ. Res. 91 (2002) 837-844
26. Gan Y., Shen Y.H., Utama B., Wang J., Coselli J., and Wang X.L. Dual effects of histone deacetylase inhibition by trichostatin A on endothelial nitric oxide synthase expression in endothelial cells. Biochem. Biophys. Res. Commun. 340 (2006) 29-34
27. Henderson C., Mizzau M., Paroni G., Maestro R., Schneider C., and Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J. Biol. Chem. 278 (2003) 12579-12589
28. Gan Y., Shen Y.H., Wang J., Wang X., Utama B., Wang J., and Wang X.L. Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase. J. Biol. Chem. 280 (2005) 16467-16475
29. Bordier C. Phase separation of integral membrane proteins in Triton X-114 solution. J. Biol. Chem. 256 (1981) 1604-1607
30. Aznar S., and Lacal J.C. Rho signals to cell growth and apoptosis. Cancer Lett. 165 (2001) 1-10
31. Hall A. Rho GTPases and the control of cell behaviour. Biochem. Soc. Trans. 33 (2005) 891-895
32. Porter K.E., Turner N.A., O'Regan D.J., Balmforth A.J., and Ball S.G. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc. Res. 61 (2004) 745-755
33. Zhong W.B., Liang Y.C., Wang C.Y., Chang T.C., and Lee W.S. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr. Relat. Cancer 12 (2005) 615-629
34. Moomaw J.F., and Casey P.J. Mammalian protein geranylgeranyltransferase. Subunit composition and metal requirements. J. Biol. Chem. 267 (1992) 17438-17443
35. Richon V.M., Zhou X., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol. Dis. 27 (2001) 260-264
36. Rosato R.R., and Grant S. Histone deacetylase inhibitors in clinical development. Expert Opin. Investig. Drugs 13 (2004) 21-38
37. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
38. Laufs U., Endres M., Custodis F., Gertz K., Nickenig G., Liao J.K., and Bohm M. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 102 (2000) 3104-3110
39. Malliri A., and Collard J.G. Role of Rho-family proteins in cell adhesion and cancer. Curr. Opin. Cell Biol. 15 (2003) 583-589
40. Ridley A.J. Rho proteins and cancer. Breast Cancer Res. Treat. 84 (2004) 13-19